Posthysteroscopy Candida Glabrata Peritonitis in a Patient on Capd

Maruyama, Haruhiko; Nakamaru, T; Oya, Muneharu; Miyakawa, Yoshikazu; Sato, Nobuaki; Ishizuka, Yasuo; Kourakata, H; Nakagawa, Yuki; Arakawa, Masaaki

doi:10.1177/089686089701700421

Cited by 13 publications

(15 citation statements)

References 5 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The literature review found an additional 14 cases (Table 1) (3-12). In only one case was antibiotic prophylaxis given prior to the procedure (7).…”

Section: Resultsmentioning

confidence: 99%

Iatrogenic Peritonitis: The Need for Prophylaxis

2000

View full text Add to dashboard Cite

“…The literature review found an additional 14 cases (Table 1) (3-12). In only one case was antibiotic prophylaxis given prior to the procedure (7).…”

Section: Resultsmentioning

confidence: 99%

Iatrogenic Peritonitis: The Need for Prophylaxis

2000

View full text Add to dashboard Cite

“…A vaginal–peritoneal communication was suspected to have allowed the distension medium to carry the fungus into the peritoneal cavity. Post-hysteroscopy C. glabrata peritonitis in a PD patient has also been described (80). The potential use of a prophylactic local antifungal agent before hysteroscopy may be important in this setting.…”

Section: Pathogenesis and Portal Of Entry Of Organismsmentioning

confidence: 98%

Fungal Peritonitis in Peritoneal Dialysis Patients

2005

View full text Add to dashboard Cite

Peritonitis is one of the most frequent complications of peritoneal dialysis (PD) and 1% – 15% of episodes are caused by fungal infections. The mortality rate of fungal peritonitis (FP) varies from 5% to 53%; failure to resume PD occurs in up to 40% of patients. The majority of these FP episodes are caused by Candida species. Candida albicans has historically been reported to be a more common cause than non-albicans Candida species, but in recent reports a shift has been observed and non-albicans Candida may now be more common. Unusual, often “nonpathogenic,” fungi are being increasingly reported as etiologic agents in FP. Clinical features of FP are not different from those of bacterial peritonitis. Phenotypic identification of fungi in clinical microbiology laboratories is often difficult and delayed. New molecular diagnostic techniques ( e.g., polymerase chain reaction) are being developed and evaluated, and may improve diagnosis and so facilitate early treatment of infected patients. Abdominal pain, abdominal pain with fever, and catheter left in situ are risk factors for mortality and technique failure in FP. In programs with high baseline rates of FP, nystatin prophylaxis may be beneficial. Each program must examine its own history of FP to decide whether prophylaxis would be beneficial. Catheter removal is indicated immediately after fungi are identified by Gram stain or culture in all patients with FP. Prolonged treatment with antifungal agents to determine response and attempt clearance is not encouraged. Antifungals should be continued for 10 days to 2 weeks after catheter removal. Attempts at reinsertion should be made only after waiting for 4 – 6 weeks.

show abstract

“…Table 3). Due to the high prevalence of Candida in the mucosal surfaces of the external genitalia, it is not surprising that there has also been multiple reports of Candida peritonitis in PD patients who underwent gynecologic procedures [52-54]. Periprocedural fungal prophylaxis is not currently a guideline recommendation, but it could be considered in those known to have candidiasis.…”

Section: Gynecologic Proceduresmentioning

confidence: 99%

Periprocedural Peritonitis Prophylaxis: A Summary of the Microbiology and the Role of Systemic Antimicrobials

Hsueh

Shah

2021

Kidney Dis

View full text Add to dashboard Cite

Background: Peritonitis is a leading complication of peritoneal dialysis (PD). One strategy that the International Society for Peritoneal Dialysis (ISPD) has used to help mitigate the morbidity and mortality associated with peritonitis is through prevention, including antibiotic prophylaxis utilization in high-risk situations. The aim of this study is to summarize our current understanding of postprocedural peritonitis and discuss the existing data behind periprocedural antibiotic prophylaxis, focusing primarily on PD catheter insertion, dental procedures, colonoscopies, upper endoscopies with gastrostomy, and gynecologic procedures. Summary: The ISPD currently recommends intravenous antibiotics prior to PD catheter insertion, colonoscopies, and invasive gynecologic procedures, though prophylaxis has only demonstrated benefit in a prospective, randomized control setting for PD catheter insertion. However, multiple retrospective studies exist that support the use of antibiotic prophylaxis for the other 2 procedures. No specific antibiotic regimen has been established as most optimal to prevent peritonitis for any of the 3 procedures. Antibiotic coverage should include the Enterobacteriaceae family, as well as Gram-positive organisms commonly found on the skin flora for PD catheter insertion, anaerobes for colonoscopies, and common organisms from the urogenital flora in gynecologic procedures. Additionally, the ISPD currently recommends oral amoxicillin prior to dental procedures. There is currently no ISPD recommendation to provide antibiotic prophylaxis prior to an upper endoscopy with or without gastrostomy, though this is a potential area for research. Key Messages: PD patients are at high risk for developing peritonitis after typical procedures. Antibiotic prophylaxis is a potential strategy that the ISPD utilizes to prevent these infections. However, further research needs to be done to determine the optimal antibiotic regimen.

show abstract

Posthysteroscopy Candida Glabrata Peritonitis in a Patient on Capd

Cited by 13 publications

References 5 publications

Iatrogenic Peritonitis: The Need for Prophylaxis

Iatrogenic Peritonitis: The Need for Prophylaxis

Fungal Peritonitis in Peritoneal Dialysis Patients

Periprocedural Peritonitis Prophylaxis: A Summary of the Microbiology and the Role of Systemic Antimicrobials

Contact Info

Product

Resources

About